According to filings with the U.S. Securities and Exchange Commission, Denali Therapeutics is raising up to $499,732,711.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Ryan Watts played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Denali Therapeutics
Denali Therapeutics is dedicated to defeating neurodegenerative diseases by breaking through historical barriers in scientific research and clinical development in order to deliver safe and effective medicines to patients and families. Our scientific approach is based on three core principles: rigorous assessment of genetic targets, engineering brain delivery, and using biomarkers to guide development. Our team thrives in a work environment that is scientifically driven, impact-focused, supportive, and collaborative. Our ability to have a positive impact on peoples lives is directly related to the trust we have in each other and our ability to unify our diverse backgrounds and experience behind our purpose to defeat degeneration.

To learn more about Denali Therapeutics, visit http://www.denalitherapeutics.com/

Contact:
Ryan Watts, President and Chief Executive Officer
650-866-8548
https://www.linkedin.com/in/ryan-watts-0385b9b0/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.